back to US directory
us clinical guidance

Primary hyperparathyroidism

Fifth International Workshop confirmation, target-organ evaluation, surgery selection, monitoring and hypercalcemia safety.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with hypercalcemic or normocalcemic primary hyperparathyroidism (PHPT). The 2022 Fifth International Workshop is international but endorsed by major US bone and endocrine organizations. Secondary and tertiary hyperparathyroidism, parathyroid cancer, pregnancy and pediatric or genetic syndromes require tailored specialist guidance.
sources for this section:Fifth PHPT Workshop 2022

The Bottom Line

  • Confirm hypercalcemic PHPT with elevated albumin-adjusted calcium and an elevated or inappropriately normal intact PTH on repeated occasions, after considering assay quality and ionized calcium when needed.
  • Exclude important mimics and contributors, including familial hypocalciuric hypercalcemia, lithium or thiazide effect, severe vitamin D deficiency, CKD and other causes of secondary PTH elevation.
  • Evaluate target organs with kidney function, urinary calcium and stone imaging as indicated, and three-site DXA with vertebral assessment when clinically appropriate.
  • Recommend parathyroidectomy for symptomatic disease and for asymptomatic patients who meet the workshop鈥檚 age, calcium, skeletal or renal criteria, provided an experienced surgeon and informed patient agree.
  • Use neck imaging only to localize abnormal glands after a surgical decision; ultrasound or sestamibi does not establish or exclude the biochemical diagnosis.
sources for this section:Fifth PHPT Workshop 2022

Practical clinical workflow

1
Repeat calcium with albumin, measure intact PTH, phosphorus, creatinine or eGFR and 25-hydroxyvitamin D, and review calcium, vitamin D, lithium, thiazide and family history.
2
Assess kidney stones or nephrocalcinosis, 24-hour urinary calcium and the familial-hypocalciuric-hypercalcemia differential, and obtain skeletal assessment at the source-specified sites.
3
Discuss surgery criteria, expected benefit, operative risk and surgeon experience; obtain localization imaging only when proceeding toward an operation.
4
When observing, monitor calcium, renal status and bone density on a structured schedule and reconsider surgery if calcium rises, fracture or stone occurs, bone density declines or kidney function worsens.
5
Use cinacalcet or antiresorptive treatment only for the target outcome and patient described by current specialist guidance; medical therapy does not duplicate curative surgery.
sources for this section:Fifth PHPT Workshop 2022

Safety boundaries and escalation

  • Marked hypercalcemia with dehydration, vomiting, weakness, arrhythmia, altered cognition or acute kidney injury requires urgent hospital assessment and cause-directed treatment.
  • Avoid dehydration and review medicines that worsen calcium or renal function, but do not impose severe calcium restriction that can raise PTH and compromise bone health.
  • Before surgery, address vitamin D and perioperative calcium risk with the endocrine and surgical team; postoperative hypocalcemia and hungry-bone syndrome need an explicit monitoring plan.
  • A young age, multigland disease, family history, jaw, pituitary, pancreatic or renal tumors should trigger consideration of genetic counseling and syndrome-specific care.
sources for this section:Fifth PHPT Workshop 2022

Localization

Use the 2022 international workshop with US endocrine-surgery standards, laboratory methods and insurer rules. The source contains both GRADE-informed and consensus recommendations, so certainty must remain visible.
sources for this section:Fifth PHPT Workshop 2022

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Fifth International Workshop on Primary Hyperparathyroidism; endorsed by the American Society for Bone and Mineral Research and American Association of Clinical EndocrinologyEvaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International WorkshopDOI 10.1002/jbmr.4677 路 published 2022-08-19 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.